Financials data is unavailable for this security.
View more
Year on year Shanghai Junshi Biosciences Co Ltd grew revenues 3.38% from 1.45bn to 1.50bn while net income improved from a loss of 2.39bn to a smaller loss of 2.28bn.
Gross margin | 67.77% |
---|---|
Net profit margin | -129.54% |
Operating margin | -121.74% |
Return on assets | -18.42% |
---|---|
Return on equity | -25.80% |
Return on investment | -23.01% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shanghai Junshi Biosciences Co Ltd fell by 2.22bn. Cash Flow from Financing totalled 711.83m or 47.37% of revenues. In addition the company used 2.00bn for operations while cash used for investing totalled 933.19m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 6.58 |
---|---|
Tangible book value per share | 6.04 |
More ▼
Balance sheet in CNYView more
Current ratio | 2.11 |
---|---|
Quick ratio | 1.87 |
Total debt/total equity | 0.3966 |
---|---|
Total debt/total capital | 0.2801 |
More ▼